Horizon EuropeTRL 5-6Biomed

TUMOR-LOCK

Tumor-lock: forbid the generation of circulating tumor

Project details

GA NUMBER

101001652

PROJECT TYPE

ERC - CONSOLIDATOR GRANT

FUNDING

€2 m

STARTING DATE

1 June 2021

DURATION

5 years

Locking tumour cells at the primary site

Metastases develop from clusters of circulating tumour cells (CTCs) that detach from the primary tumour and travel through the bloodstream to new tissues. Once a tumour has metastasised, the chances of cure are significantly reduced. While the clinical and biological properties of CTCs are well understood, how they arise from a solid tumour mass is still unknown. Dr Nicola Aceto and his group have found that specific signals trigger the formation of CTCs, rather than being random. Their project aims to identify the cell-autonomous and non-cell-autonomous mechanisms behind these signals in order to develop new therapies that block the tumour cells in situ and prevent them from spreading.

Partners

Eidgenössische Technische Hochschule Zürich

Our role

What we did to make this project TRULY INNOVATIVE.

Development of a pitch deck for investors, including custom images and brand identity for the new company.

Milestones step by step

A quick overview of the goals achieved by working on this project.

Metastasis can be prevented. We know how.

Nicola Aceto, ETH Zurich